Anti IFI16 ELISA Assay
The Anti IFI16 ELISA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: 1.16 AU/mL
Dynamic Range: 50 – 80 AU/ml
Incubation Time: 1.5 hour
Sample Type: Serum, Plasma
Sample Size: 10 µl
Controls Included
Assay Background
The Anti IFI16 ELISA is a semi-quantitative, enzyme-linked immunosorbent assay (ELISA) for the detection of IgG class antibodies directed against the IFI16 antigen in human serum or plasma. Systemic autoimmune disease is characterized by the presence of circulating autoantibodies. Systemic Sclerosis (SSc) is an autoimmune multisystem connective tissue disorder characterized by inflammatory and fibrotic processes, affecting the skin, blood vessels and internal organs. The two widely recognized subsets of SSc are limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc). These two forms of SSc present divergent patterns of internal organ involvement, clinical course and autoantibody profiles, as defined by the Le Roy criteria (LeRoy et al. 2001). SSc is characterized by the occurrence of antinuclear autoantibodies. Anti-centromere (ACA), anti-DNA topoisomerase-I (anti-Scl70) are the most common autoantibodies and, along with anti-RNA polymerases (RNAP I-III), are specific to SSc.
Several cellular activities have been assigned to IFI16, including roles in antiviral, inflammatory and apoptotic processes. Anti IFI16 antibodies have been described in the sera of patients affected by systemic autoimmune disorders (reviewed in Mondini et. 2007). Although the subcellular localization of the IFI16 autoantigen is well recognized as nuclear, Anti IFI16 cannot be classified as a classical anti-nuclear antibody (ANA), because it lacks HEp-2 staining, the gold standard for identifying ANAs (Costa et al. 2011). In patients with a diagnosis of Systemic Sclerosis (SSc), Anti IFI16 antibodies have been detected with a prevalence up to 29% (Mondini et al. 2006, Costa et al. 2011). A subgroup of SSc patients (34% of the entire population, Costa et al. 2011) tests negative for ACA and anti-Scl70 (double negative patients, dnSSc). Anti IFI16 antibodies are found in up to 30% of the dnSSc patients and, in this subgroup, are significantly associated with the limited cutaneous SSc subset (Mondini al. 2006, Costa et al. 2011). Moreover, Anti IFI16 have been shown to segregate with a different population in respect to anti-RNAP III (Costa et al. 2011). Thus, the detection of Anti IFI16 can aid in differentiating the SSc subtypes in conjunction with clinical and laboratory findings, being useful for disease classification in patients negative for other serological markers of SSc (Costa et al. 2011).
Related Products
Anti-MPO pANCA ELISA Assay
Anti-PR3 cANCA ELISA Assay
Anti-CP IgG ELISA Assay
Product Developed and Manufactured in Italy by Diametra
